Significant accumulation of Far1p is restricted to the G 1 phase of the Saccharomyces cerevisiae cell cycle. Here we demonstrate yeast cell cycle regulation of Far1p proteolysis. Deletions within the 50 N-terminal amino acids of Far1p increase stability and reduce cell cycle regulation of Far1p abundance. Whereas wild-type Far1p specifically and exclusively promotes G 1 phase arrest in response to mating factor, stabilized Far1p promoted arrest both during and after G 1 . The loss of the G 1 specificity of Far1p action requires elimination of FAR1 transcriptional regulation (by means of the GAL1 promoter) as well as N-terminal truncation. Thus, the cell cycle specificity of mating factor arrest may be largely due to cell cycle regulation of FAR1 transcription and protein stability.
The Start control point late in the G 1 stage of the budding Saccharomyces cerevisiae cell cycle commits cells to DNA replication and mitosis. Execution of Start is inhibited by mating factors, which stimulate exit from the cell cycle and entry into a differentiation pathway leading to conjugation (28, 33) . Execution of a potentially comparable commitment step in mammalian cells (24) is inhibited by cell-cell contact and by transforming growth factor ␤ (16).
Progression through both Start and mitosis is driven by cyclin-dependent protein kinases (CDKs) (7, 20, 31) . CDKs are activated by cyclin binding (20, 31) . In budding yeast cells, cyclins coded for by the CLN gene family are necessary for Start, while CLB family B-type cyclins are required for later cell cycle transitions (20) .
Physiological G 1 arrest can result from interference with the formation or function of cyclin-CDK complexes necessary for entry into the S phase (6, 14) . Cyclin-CDK inhibition may be mediated by CDK-binding proteins (21) . Transforming growth factor ␤ activates p27 Kip1 , which can inhibit cyclin-CDK complexes present in mammalian cells during G 1 (27) . The ␣ mating factor induces binding of the yeast Far1p to Cln-Cdc28 kinase complexes, inhibiting their activity (25, 26, 35) .
In many cases, such as transforming growth factor ␤ treatment in mammalian cells or mating factor treatment of budding yeast cells, cell cycle arrest is specific to the G 1 interval, although CDKs are necessary not only for entry into S from G 1 but also for entry into mitosis from G 2 . In budding yeast cells, levels of the CDK-binding protein Far1p rapidly decline as cells pass through Start because of transcriptional and posttranscriptional control of FAR1 expression (18) . Since Far1p is necessary for cell cycle arrest by ␣-factor (2), the G 1 specificity of cell cycle arrest by ␣-factor might be due to the loss of Far1p at Start (1, 18) . Here we test this hypothesis by means of mutations in FAR1 that interfere with cell cycle regulation of Far1p stability.
MATERIALS AND METHODS
Yeast strains and plasmids. Standard methods were used for strain constructions (9) . All strains were isogenic with BF264-15Dau (18) . pFC24 is the GAL1::FAR1 plasmid based on the original FAR1 sequence (3) . We have renamed this cassette GAL1::FAR1/⌬N for clarity. The integrating LEU2::GAL1:: FAR1/⌬N plasmid pJM305 was constructed by ligating a PvuI fragment from pFC24 (3) into the PvuI sites of pRS305 (32) . To make the integrating LEU2::GAL1::FAR1/ϩN plasmid pJM306, the first 893 bp of FAR1 coding sequences were amplified from pFC21 (2) (provided by F. Chang) by PCR. The PCR oligonucleotides were 5Ј-TTACTCGAGATCTATTAATGAAGACAC CAA-3Ј (sense strand) and 5Ј-CCTGTGAAGCTTCTCGCCG-3Ј (non-sense strand). The initiation codon and restriction sites are underlined. The sense strand oligo generated a new XhoI site. The non-sense strand PCR oligo spanned a HindIII site within the FAR1 coding sequences (2) . The amplified fragment was cut with XhoI and HindIII and ligated into the XhoI-HindIII sites of pJM305 to generate pJM306. For integration at leu2, pJM305 and pJM306 were cut with ClaI.
The N-terminal deletion series in GAL1::FAR1 was constructed in the same manner as pJM306, except that the sense strand oligos used for PCR corresponded to nucleotides (nt) 34 to 49, 64 to 79, 94 to 109, and 124 to 139 (numbering from the FAR1/ϩN ATG initiation codon) in the sequence 3Ј to the FAR1/ϩN ATG (see above).
The ⌬30 and ⌬40 mutations were introduced into the endogenous FAR1 gene in the following manner. FAR1 was disrupted with the plasmid pJM340 containing URA3 between two HindIII sites, one 5Ј of the FAR1/ϩN ATG and the other in the FAR1 coding sequence. The FAR1 gene (KpnI to BglII) was cloned in a plasmid containing the LEU2 gene, producing YIpJM343. Oligonucleotides corresponding to the FAR1 sense strand from a HindIII site 5Ј of the ATG to the ATG, then corresponding to nt 94 to 109 (⌬30) or nt 124 to 139 (⌬40), were used in a PCR together with the same 3Ј oligonucleotide used for pJM306, with pFC15 (from F. Chang) being used as the template. PCR mixtures were digested with HindIII and cloned into HindIII-cut YIpJM343 to make YIpJM346 (⌬30) and YIpJM347 (⌬40). YIpJM343, -346, and -347 were digested with StuI and used to transform 1630-9C-1 (MATa bar1 far1::URA3). Transformants of a far1::URA3 disruptant with these plasmids were streaked on 5-fluoroorotic acid to select popouts of URA3. Leu Ϫ popouts restored the FAR1, FAR1⌬30, or FAR1⌬40 coding sequence with the wild-type FAR1 promoter.
DNA sequencing. DNA sequencing of wild-type FAR1 in pFC21 was done with a Pharmacia T7 Sequencing Kit. The primer was 5Ј-ACTCTCTTCAATATAC CCAAATGTGGGCAT-3Ј, hybridizing to FAR1 nt 463 to 492 (2) .
Cell culture and cell cycle synchronization. Cells were grown in yeast extractpeptone (YEP) medium with 2% glucose, 3% galactose, or 3% raffinose (Sigma). Synchronization by the cln block-release protocol was done as described elsewhere (18) .
For synchronization by centrifugal elutriation, the cells were grown to an A 660 of ϳ1.0 in 1.5 liters of YEP-galactose at 30ЊC, collected by filtration through 0.65-m-pore-size filters (Millipore), resuspended in 200 ml of fresh YEP-galactose, sonicated to disperse clumps, and loaded at 30ЊC at a pump speed of 50 ml/min into a Beckman JE5.0 elutriator rotor running at 3,000 rpm. After being loaded, the cells were equilibrated in the chamber for 10 to 15 min with YEPgalactose, and cell fractions were stepped off by incremental increases in pump speed. Fractions with the highest percentage of unbudded cells were reinoculated into fresh YEP-galactose and incubated at 30ЊC.
The percentages of unbudded and budded cells were determined as described previously (18) . The percentage of binucleate cells was determined by nuclear staining with 4Ј,6-diamidino-2-phenylindole (DAPI) (Sigma) as described previously (18) . The determination of the cellular DNA content was done by flow cytometry as described previously (5).
␣-Factor response assays. For an analysis of ␣-factor arrest on solid medium, cells were grown to mid-log phase (A 660 of 0.5 to 1.0 at 30ЊC) in YEP-galactose, sonicated to disperse clumps, and plated on YEP-galactose and YEP-glucose with and without 0.1 M ␣-factor (Sigma). The plates were incubated at 30ЊC for 2.5 h (YEP-glucose) and 3.5 h (YEP-galactose) and examined microscopically. The difference in the incubation times for YEP-glucose and YEP-galactose reflects cell doubling times (ϳ100 min on YEP-glucose and ϳ150 min on YEPgalactose).
For an analysis of ␣-factor arrest in liquid cultures, ␣-factor was added to early-log-phase (A 660 of ϳ0.3) YEP-galactose cultures, and incubation was continued for 2.5 h before the cells were fixed.
For the determination of the percentage of budded cells that divide during ␣-factor treatment, we assumed that essentially all cells that were unbudded at the time of the ␣-factor addition arrested without undergoing bud emergence. We assume this because the percentage of single unbudded cells did not change over time when GAL1::FAR1/ϩN and GAL1::FAR1/⌬N cells were plated on YEP-galactose with ␣-factor (see Fig. 2 ) (data not shown). The fraction of budded cells in the initial population that divide and then arrest in the unbudded state after the ␣-factor challenge can be calculated as follows, assuming that a budded cell that divides will generate two arrested unbudded cells. With a starting population of 100 cells, the number of cells arresting in the unbudded state after ␣-factor treatment is U beg ϩ 2 ⅐ F ⅐ B beg , and the total number of cells after ␣-factor treatment (budded plus unbudded) is 100 ϩ F ⅐ B beg , where U beg is the percentage of unbudded cells before ␣-factor treatment, B beg is the percentage of budded cells before ␣-factor treatment, and F is the fraction of budded cells that divide during ␣-factor treatment. The percentage of unbudded cells after ␣-factor treatment (U end ) is therefore represented by U end ϭ 100(U beg
Antibodies and Western blot (immunoblot) analysis. Anti-Far1p (51-830) rabbit polyclonal antibodies were raised and affinity purified as described previously (3).
Anti-Far1p (10-24) rabbit polyclonal antisera were raised against a peptide (amino acids 10 to 24 of Far1p) coupled to keyhole limpet hemocyanin (Immuno-Dynamics Inc., La Jolla, Calif.). The detection of proteins on Western blots following transfer to Immobilon (Millipore) was by alkaline phosphatase-5-bromo-4-chloro-3-indolylphosphate toluidinium-nitroblue tetrazolium staining as described previously (18) or by chemiluminescence detection (Amersham) following the manufacturer's instructions. Equal amounts of cell culture were extracted for each point in the Western blotting experiments. Equal loading of the gels was established by examination of the intensity of nonspecific bands detected by the immunoblot procedure and by Auro-dye (Amersham) staining of a backup Immobilon strip (data not shown). In general, extraction of equal optical density units of cells resulted in only minor variations in the yields of the protein extracted (data not shown). (Fig. 1A) . Under electrophoresis on sodium dodecyl sulfate-polyacrylamide gels, wild-type Far1p and Far1p/ϩN (from GAL1::FAR1/ϩN) comigrated, but Far1p/⌬N migrated aberrantly (Fig. 1B ). An antibody raised against Far1p amino acids 10 to 24 recognized wild-type Far1p and Far1p/ϩN but not Far1p/⌬N (Fig. 1B) , confirming the revised sequence.
RESULTS

Correction of the
Phosphorylation of Far1p as cells pass through Start causes a reduction in Far1p gel mobility (17, 18) . The epitope recognized by anti-Far1p (10-24) was cell cycle regulated, since at Start, as Far1p gel mobility decreased, recognition of (shiftedup) Far1p by anti-Far1p (10-24) but not by anti-Far1p (51-830) was lost (Fig. 1C ).
Figure 1B also shows that GAL1::FAR1 cells moderately but detectably overexpress Far1p by comparison with G 1 -arrested cells. Far1p levels in G 1 -arrested GAL1::FAR1 strains do not differ markedly from the levels in cycling cells (see Fig. 6 ) (data not shown).
N-terminal truncation of Far1p increases its functional stability.
We examined the ability of previously synthesized Far1p to arrest the cell cycle in response to ␣-factor in the absence of new Far1p synthesis ( (18) . The cell cycle-constitutive GPD promoter was used in this experiment because it gives a prominent Far1p mobility shift in this protocol (17) . At 0, 12, 24, and 36 min (lanes 1, 2, 3, and 4) after the release from the G 1 block, protein samples were extracted and Western blotted with antiFar1p (51-830) (upper panel) and anti-Far1p (10-24) (lower panel).
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galactose and YEP-glucose solid media containing or not containing ␣-factor (glucose rapidly shuts off the GAL1 promoter [13] , and GAL1::FAR1 transcripts dropped within 15 min to a very low and nonfunctional level upon transfer to glucose). When plated on galactose medium plus ␣-factor (continuous When plated on glucose medium plus ␣-factor (blocking new Far1p synthesis), GAL1::FAR1/ϩN cells that were unbudded at the time of plating did not bud after plating, whereas most cells that were budded at time of plating produced multiple new buds after plating (Fig. 2B [shaded bars] ). This result suggests that Far1p/ϩN present in unbudded (G 1 ) cells at the time of plating was stable and functional for several hours after the cessation of new synthesis and that Far1p/ϩN present in budded cells (post-G 1 ) at the time of plating was insufficiently abundant or stable to promote a delay or the arrest of cell cycle progression. Thus, when plated on glucose plus ␣-factor, unbudded cells arrested while budded cells continued to proliferate.
In contrast, GAL1::FAR1/⌬N cells plated on glucose plus ␣-factor medium arrested as a mixture of singlets and doublets without new bud emergence, just as when they were plated on galactose plus ␣-factor medium (Fig. 2D [shaded bars] ). Thus, previously synthesized Far1p/⌬N could promote at least 2 h of cell cycle arrest in response to ␣-factor, without new synthesis, at cell cycle positions other than G 1 .
These results suggest that Far1p/ϩN is more stable in unbudded (G 1 ) cells than at other points in the cell cycle and that Far1p/⌬N is relatively stable even in the budded interval of the cell cycle. Biochemical confirmation of this suggestion is presented below.
N-terminal truncation of Far1p interferes with the G 1 phase specificity of cell cycle arrest by ␣-factor. GAL1::FAR1/ϩN, GAL1::FAR1/⌬N, and wild-type FAR1 cells all showed similar dose responses for arrest by ␣-factor as measured by a halo assay (Fig. 3Q to T) . However, in response to ␣-factor, a significant proportion of GAL1::FAR1/⌬N cells arrested in the budded state with a DNA content greater than 1 N (Table 1 and Fig. 3 ). GAL1::FAR1/⌬N cells that arrested in the budded state were almost all mononucleate (as revealed by DAPI staining of nuclei), indicating that budded cells had not yet executed nuclear division (data not shown). The abnormal arrest of GAL1::FAR1/⌬N cells in the budded post-G 1 interval of the cell cycle was not due simply to overexpression of FAR1 from the GAL1 promoter, since GAL1::FAR1/ϩN cells responded normally to ␣-factor by arresting as unbudded G 1 cells (Table 1 and Fig. 3) .
The budded-cell-arrest phenotype due to the integrated GAL1::FAR1/⌬N cassette was somewhat sensitive to copy number, with two copies giving a more severe and reproducible phenotype (data not shown). All experiments reported here use a two-copy integrant. In contrast, even multiple copies of GAL1::FAR1/ϩN gave exclusively G 1 unbudded arrest (data not shown). It is important to note that even with two copies, the GAL1::FAR1 cassettes gave only a moderate overexpression of Far1p by comparison with peak expression from the endogenous promoter (Fig. 1) .
Budded cell arrest is not due to a failure of Far1p/⌬N to arrest the cell cycle in G 1 before bud emergence for the following reasons. The budded-cell-arrest phenotype conferred by the GAL1::FAR1/⌬N allele was largely dominant over wildtype FAR1 ( Table 1 ), indicating that budded cell arrest was not due to a deficiency in the ability of truncated Far1p to promote normal G 1 arrest. Consistent with this, budded cell arrest (even in GAL1::FAR1/⌬N far1::URA3 strains) required high concentrations of ␣-factor (ϳ10 Ϫ7 M) (data not shown); at lower concentrations of ␣-factor (ϳ10 Ϫ8 M), budded GAL1::FAR1/ ⌬N cells divided and then arrested efficiently in the succeeding unbudded G 1 interval. This result indicates that truncated Far1p is fully able to promote G 1 arrest. GAL1::FAR1/⌬N cells did not undergo new rounds of bud emergence when treated with ␣-factor (Fig. 2D) , indicating that budded cell arrest is not due to a leak-through of cells that were in G 1 but failed to arrest. GAL1::FAR1/ϩN cells (as well as wild-type cells) were quantitatively arrested in G 1 by concentrations of ␣-factor greater than or equal to 10 Ϫ8 M (data not shown). A subpopulation of budded GAL1::FAR1/⌬N cells divided before arresting in ␣-factor as G 1 cells. To determine if this heterogeneity reflected cell cycle position, we synchronized cultures by centrifugal elutriation. Division of budded GAL1:: FAR1/⌬N cells was blocked by ␣-factor treatment early in the budded interval but was not blocked later (Fig. 4) , accounting for the ability of some GAL1::FAR1/⌬N cells from an asynchronous culture to divide in ␣-factor before arresting in G 1 . In contrast, essentially all budded GAL1::FAR1/ϩN cells divided in the presence of ␣-factor and then arrested as G 1 unbudded cells, irrespective of cell cycle position at the time of ␣-factor challenge (Fig. 4) . This result suggests that GAL1::FAR1/⌬N cells are not uniformly sensitive to non-G 1 arrest throughout the cell cycle but are more sensitive early in the budded interval.
Thus, deletion of the Far1p N terminus results in the acquisition of a novel function: the ability to block division in cells that have already passed Start and initiated DNA replication and budding.
Far1p/؉N specifically delays Start in the absence of mating factor. GAL1::FAR1/ϩN cells were large (about 175% of wildtype volume by Coulter Channelyzer) (data not shown) and exhibited a significant delay in G 1 compared with wild-type cells (Fig. 3) , while deletion of FAR1 caused a small but reproducible decrease in the proportion of unbudded G 1 cells (Fig. 3 and Table 1 ). Thus, Far1p may delay the Start transition in a dose-dependent manner even in the absence of ␣-factor.
Specific delay in G 1 by GAL1::FAR1 required the Far1p N terminus. GAL1::FAR1/⌬N cells were about as large as GAL1::FAR1/ϩN cells (about 150% of wild-type volume) (data not shown), and yet GAL1::FAR1/⌬N cells showed a greater proportion of budded cells with 2 N (G 2 -M) DNA content compared with wild-type cells (Fig. 3 and Table 1 ).
This could reflect the ability of truncated Far1p to inhibit cell division as well as Start, as was observed in the presence of mating factor (see above). In the absence of mating factor, these effects of both GAL1::FAR1/ϩN and GAL1::FAR1/⌬N were only temporary delays (as opposed to the blocks seen with mating factor), since in the absence of mating factor, the doubling times of these strains were the same as the doubling time of wild-type cells (data not shown).
Deletion mapping within the Far1p N terminus. To begin to determine what subregions within the 50 Far1p N-terminal amino acids could control cell cycle specificity of mating factor arrest, we deleted the N-terminal 10, 20, 30, or 40 amino acids. We integrated these GAL1::FAR1 genes and tested transformants for cell cycle specificity of arrest after incubation in mating factor, scoring the percentage of budded cells and the percentage of mononucleate budded cells. (Binucleate budded cells could arise from a block to cytokinesis without a block to nuclear division.) We observed a roughly progressive increase in the severity of the phenotype with the increasing length of a Values are the means Ϯ the standard errors of the mean (n ϭ 4). The strains were all MATa bar1, with other genotypes as indicated. Log-phase YEP-galactose cultures were incubated for 2.5 h with and without 0.5 M ␣-factor at 30ЊC.
b The percentages of budded cells that divide in ␣-factor were calculated as described in Materials and Methods. This calculation was not applicable (NA) to far1::URA3 cells, which fail to arrest in ␣-factor (2). the deletion up to 30 amino acids (Fig. 5) . DNA flow cytometry (data not shown) confirmed an approximate correlation between the number of budded cells and the number of cells with greater than G 1 (at or near G 2 ) DNA content. N-terminal truncation increases the stability of Far1p. Wild-type Far1p accumulates efficiently only in G 1 phase cells (18) , and we were therefore surprised to find phenotypic evidence for the function of N-terminally truncated Far1p late in the cell cycle. We examined the stability of wild-type and Nterminally truncated Far1p by turning off synthesis of GAL1::FAR1 by adding glucose (repressing the GAL1 promoter) (Fig. 6A) . GAL1::FAR1 transcripts declined to very low levels within 15 min of the glucose addition (data not shown), allowing us to monitor decay of previously synthesized Far1p in the absence of new Far1p synthesis. We observed rapid decay of wild-type Far1p; this decay was dependent on Cdc28 function and/or progression out of G 1 , as blocking a cdc28-4 temperature-sensitive strain in G 1 by incubation at 35ЊC stabilized Far1p (Fig. 6B) . The N-terminal deletion series described above, except for Far1p⌬10, displayed clearly increased Far1p stability; FAR1/⌬10 displayed only a modest non-G 1 -arrest phenotype (Fig. 5) . Far1p⌬30 was the most stable of the series (Fig. 6 and data not shown) . The stability of Far1p⌬40 was increased in cdc28-blocked cells by comparison with cells in cycling cultures (Fig. 6B) , suggesting that Cdc28-cell cycle control of stability of this protein was reduced but not eliminated.
The increased stability of Far1p⌬30 compared with Far1p⌬40 suggests that the N-terminal deletions may not simply inactivate an autonomously acting instability determinant. This is consistent with the result that the 50 N-terminal amino acids of Far1p did not confer instability when fused to ␤-galactosidase (data not shown). Other regions of Far1p may also be required for instability.
Far1p⌬N (with the first 50 amino acids deleted) displayed a stability similar to that of Far1p⌬40 in this protocol (data not shown).
Cell cycle regulation of N-terminally truncated Far1p under control of the endogenous FAR1 promoter. We introduced the FAR1⌬30 and FAR1⌬40 N-terminal coding sequence deletions into the FAR1 gene by precise gene replacement so that the mutant proteins would be under the control of the wild-type FAR1 promoter instead of the GAL1 promoter (see Materials and Methods). Using these strains, we examined cell cycle FIG. 5 . FAR1 N-terminal deletion series. A MATa bar1 far1::URA3 strain (1640-4A) was transformed with GAL1::FAR1 containing the indicated N-terminal deletion. Transformants containing two tandem copies of the GAL1::FAR1 cassette integrated at leu2 were analyzed as described in the legend to Fig. 4 . The use of two-copy integrants was not essential but tightened the phenotype and also made it more reproducible for most mutants. The percentage of mononucleate budded cells in ␣-factor is defined as the proportion of budded cells with a single undivided nucleus (as determined by DAPI staining) out of the total population of cells. Calculation of the percentage of budded cells that divide in ␣-factor is explained in Materials and Methods. An independent PCR construct of ⌬10 gave a much weaker non-G 1 arrest response; independent PCR constructs of ⌬20, ⌬30, and ⌬40 gave results comparable to those presented here. ⌬N was the original GAL1::FAR1 cassette constructed by Chang and Herskowitz (3). Unlike strains expressing Far1p⌬30 or Far1p⌬40 from the GAL1 promoter, strains expressing these proteins from the endogenous FAR1 promoter exhibited only very minor differences from wild-type strains, arresting with Ն90% of unbudded cells upon ␣-factor treatment (data not shown). The relevant difference between the GAL1 promoter and the FAR1 promoter could be the moderate overexpression due to the GAL1 promoter (Fig. 1) or the cell cycle deregulation of the GAL1 promoter compared with the FAR1 promoter (18) . Thus, effective elimination of G 1 specificity may require elimination of both controls on FAR1 abundance reported previously (18) : the control of Far1p abundance and transcriptional control of FAR1 expression.
DISCUSSION
Regulated instability of Far1p. Far1p is stable during the pre-Start G 1 interval of the yeast cell cycle but becomes unstable as cells pass through Start and commit to cell cycle progression. Deletions within the first 50 amino acids generate stabilized proteins with a reduced cell cycle regulation of abundance.
Far1p blocks Start by binding to and inhibiting Start-promoting Cln-Cdc28 kinase complexes (25, 26, 35) . N-terminally truncated Far1p may promote post-Start cell cycle arrest by similarly inhibiting B-type cyclin-Cdc28 kinase complexes functioning in post-Start cells (20) . Alternatively, N-terminally truncated Far1p may exert its effects by blocking the action of Cln-Cdc28 kinases at points of the cell cycle after wild-type Far1p has been degraded (the peak of CLN1 and CLN2 expression follows the decline in Far1p levels [18] ).
We cannot rule out the possibility that post-Start arrest of cells expressing N-terminally truncated Far1p is not solely due to the stabilization of Far1p but is due also to an aberrant function of the mutant protein. For example, the N-terminal deletions could reduce the specificity of Far1p inhibition such that Clb-Cdc28 kinases as well as Cln-Cdc28 kinases could be inhibited by ␣-factor-activated Far1p. To test this by the assay of Peter and Herskowitz (26) requires the introduction of N-terminal deletions into the FAR1-22 constitutively active mutant version of FAR1 so that the assay of bacterially produced protein (by bypassing the requirement for mating factor pathway activation [26] ) would be allowed. For this reason, we have not yet tested this possibility biochemically. Although Peter and Herskowitz (26) failed to detect inhibition of a Clb2-Cdc28 kinase preparation in vitro with a recombinant full-length Far1p, this result cannot rule out the possibility that such inhibition could occur in vivo. We consider it likely (although still unproven) that the mechanism of post-Start arrest by truncated Far1p is similar to the mechanism of pre-Start arrest. Clearly, both mechanisms are still dependent on the mating factor pathway, as overexpression of neither full-length nor truncated Far1p has any significant effect on the doubling time in the absence of mating factor.
Mating in yeast cells is restricted to the G 1 phase (29) . Since Far1p has a role in mating distinct from its cell cycle arrest function (2), Far1p cell cycle regulation may also contribute to the block to mating outside of G 1 ; however, our preliminary attempts to detect mating in GAL1::FAR1⌬N cells outside of G 1 have been unsuccessful (data not shown).
Cdk-binding proteins and cell cycle specificity. Far1p is one of a number of proteins that interact physically with and inhibit CDKs in mammalian and yeast cells (21) . The p40-SIC1 inhibitor of B-type cyclin-Cdc28 activity in yeast cells (19, 22, 30) presents an interesting parallel to Far1p. Its levels are cell cycle regulated, being high from mid-mitosis until Start. It is degraded at Start, as is Far1p (4, 18, 30) . A significant difference is that Sic1 functions to block Clb-Cdc28 kinases independent of external signals whereas Far1p inhibition of Cln-Cdc28 kinases is ␣-factor dependent (2).
Cell cycle-regulated expression might be important for the proper function of some mammalian CDK-binding proteins. Expression of Cdi1 (a mammalian CDK-binding protein) is cell cycle regulated, and constitutive expression of Cdi1 affects cell cycle progression (10) . Cell cycle-regulated expression could contribute to restricting the function of CDK-binding proteins to appropriate cell cycle intervals in the cases of CDKbinding proteins like p21 and Cdi1, which can associate with CDKs functioning at both the G 1 -S and G 2 -M transitions (8, 11, 36) . mRNA for p21 is cell cycle regulated (15) in a pattern similar to that for FAR1 (18) : high in G 1 , low in S, and rising again in G 2 -M. p27
Kip1 levels were reported to be constant during the cell cycle (34) , but p27
Kip1 may exhibit some specificity of inhibition or increased affinity for G 1 -S-acting cyclinCdk complexes (27, 34) .
The efficiency and specificity of mating factor arrest of budding yeast cells are remarkably high, with essentially quantitative cell cycle arrest occurring exclusively in the first G 1 phase following mating factor addition (28) . Accurate cell cycle regulation of Far1p abundance (high in G 1 , low elsewhere) may be important for both efficiency and specificity; we showed previously that moderate reduction of Far1p peak abundance in G 1 compromises the efficiency of arrest (18) , and we show here that sufficient ectopic expression of Far1p outside of the G 1 interval may compromise the G 1 specificity of arrest (on the assumption that the N-terminal mutations affect only Far1p stability rather than intrinsic specificity of action). Regulation of FAR1 abundance may provide a redundant control together with the block to mating factor signalling at cell cycle Start (23); these controls could act together to provide high G 1 specificity of mating factor arrest.
